Sarcoidosis complicating treatment with natalizumab for Crohn's disease

被引：13
|
作者：
Parisinos, C. A.
Lees, C. W.
Wallace, W. A. H. [2 ]
Satsangi, J. [1 ]
机构：
[1] Univ Edinburgh, Western Gen Hosp, Gastrointestinal Unit, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Royal Edinburgh Infirm, Dept Lab Med Pathol, Edinburgh, Midlothian, Scotland
来源：
THORAX | 2011年 / 66卷 / 12期
关键词：
D O I：
10.1136/thx.2010.155762
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients.
引用
收藏
页码：1109 / 1110
页数：2
相关论文
共 50 条
  • [1] Sarcoidosis complicating treatment with adalimumab for Crohn's disease
    McDonnell, M. J.
    Rutherford, R. M.
    O'Regan, A.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 (09): : 1140 - 1141
  • [2] Natalizumab for the treatment of Crohn's disease
    Bickston, Stephen J.
    Muniyappa, Kishor
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (04) : 513 - 519
  • [3] Natalizumab in the treatment of Crohn's disease patients
    Pagnini, Cristiano
    Arseneau, Kristen O.
    Cominelli, Fabio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (11) : 1433 - 1438
  • [4] Natalizumab for the treatment of multiple sclerosis and Crohn's disease
    Keeley, KA
    Rivey, MP
    Allington, DR
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (11) : 1833 - 1843
  • [5] Natalizumab (Tysabri) for Crohn's disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2008, 50 (1285): : 34 - 36
  • [6] Natalizumab for active Crohn's disease
    Lew, EA
    Stoffel, EM
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (16): : 1599 - 1599
  • [7] Natalizumab for the treatment of Crohn's disease. Report of three cases
    Fluxa, Daniela
    Ibanez, Patricio
    Flores, Lilian
    Figueroa, Carolina
    Lubascher, Jaime
    Kronberg, Udo
    Simian, Daniela
    Pizarro, Gonzalo
    Toche, Paola
    Quera, Rodrigo
    REVISTA MEDICA DE CHILE, 2017, 145 (04) : 538 - 543
  • [8] Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
    Targan, Stephan R.
    Feagan, Brian G.
    Fedorak, Richard N.
    Lashner, Bret A.
    Panaccione, Remo
    Present, Daniel H.
    Spehlmann, Martina E.
    Rutgeerts, Paul J.
    Tulassay, Zsolt
    Volfova, Miroslava
    Wolf, Douglas C.
    Hernandez, Chito
    Bornstein, Jeffrey
    Sandborn, William J.
    GASTROENTEROLOGY, 2007, 132 (05) : 1672 - 1683
  • [9] Infliximab treatment of severe bleeding complicating Crohn's disease
    Julian-Gomez, L.
    Atienza, R.
    Barrio, J.
    Gil, P.
    Gomez de la Cuesta, S.
    Pinto, P.
    Alcaide, N.
    Caro-Paton, A.
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2010, 102 (01) : 57 - 58
  • [10] Natalizumab for induction of remission in Crohn's disease
    Nelson, Seana M. L.
    Nguyen, Tran M.
    McDonald, John W. D.
    MacDonald, John K.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (08):
12345